Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11344685
(Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2040
(17 years from now) | |
US11439777 | TEVA PHARM | Drug delivery device with electronics |
May, 2040
(17 years from now) | |
US11464923 | TEVA PHARM | Inhaler system |
Jun, 2040
(17 years from now) | |
US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(17 years from now) |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminating the treatment area with narrowband red light
Dosage: GEL;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11344685
(Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2040
(17 years from now) | |
US11439777 | TEVA PHARM | Drug delivery device with electronics |
May, 2040
(17 years from now) | |
US11464923 | TEVA PHARM | Inhaler system |
Jun, 2040
(17 years from now) | |
US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10940124 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
US10780064 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
US10966942 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) | |
US10925842 | AXSOME | Bupropion as a modulator of drug activity |
Jan, 2040
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11241400 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
US11478436 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
US11090278 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
US11464752 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 17 April, 2020
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10869845 | ENDO VENTURES | Ephedrine compositions and methods |
Jan, 2040
(16 years from now) |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 16 October, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(17 years from now) |
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 05 November, 2021
Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; Indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; Indicated for the preventive treatment of migraine in patients 12 years and older
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10945987 | GALDERMA LABS LP | Method for providing early onset of action in the treatment of rosacea |
Feb, 2040
(17 years from now) | |
US10933046 | GALDERMA LABS LP | Method for treatment of rosacea in patients aged 65 years and older |
Feb, 2040
(17 years from now) | |
US11426378 | GALDERMA LABS LP | Method for long-term treatment of rosacea |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Feb 22, 2022 |
New Indication (I) | Oct 18, 2022 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
Market Authorisation Date: 08 January, 2014
Treatment: Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11497737 | AADI | NA |
Oct, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Nov 22, 2024 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11202770 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Dec, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(17 years from now) | |
US11497745 | MIRUM | NA |
Feb, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 29, 2026 |
Orphan Drug Exclusivity (ODE) | Sep 29, 2028 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: September, 2025
Market Authorisation Date: 29 September, 2021
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11236091 | AMGEN INC | Solid state forms |
May, 2040
(17 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 28, 2026 |
Orphan Drug Exclusivity (ODE) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11141457 | AMRYT | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jun 26, 2023 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11439777 | TEVA BRANDED PHARM | Drug delivery device with electronics |
May, 2040
(17 years from now) | |
US11464923 | TEVA BRANDED PHARM | Inhaler system |
Jun, 2040
(17 years from now) | |
US11173259 | TEVA BRANDED PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103452 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(17 years from now) |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11266635 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11426390 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11433056 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11344536 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(17 years from now) | |
US11395818 | DECIPHERA PHARMS | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
Dec, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 15, 2025 |
Orphan Drug Exclusivity (ODE) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib; Treatment of gastrointestinal stromal tumors in patients suffering from palmer-planter erythrodysesthesia syndrome; Treatment of gastrointestinal stromal tumors in patients being treated concurrently with a cyp3a4 inhibitor; Method of treating gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 myalgia while being administered ripretinib daily; Treatment of gastrointestinal stromal tumors in patients suffering from hypertension
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11278547 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(17 years from now) | |
US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(17 years from now) |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 29, 2026 |
Orphan Drug Exclusivity (ODE) | Oct 29, 2028 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: October, 2025
Market Authorisation Date: 29 October, 2021
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10940133 | JAZZ | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11255842 | RADIUS HEALTH INC | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
Jan, 2040
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 28, 2022 |
M | Sep 20, 2024 |
Drugs and Companies using ABALOPARATIDE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Use for detecting neutralizing antibodies
Dosage: SOLUTION;SUBCUTANEOUS
Click on the highlighted region to filter.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
USD961376 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Aug, 2040
(17 years from now) | |
US11439758 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for precision dose delivery |
Aug, 2040
(17 years from now) | |
US11433186 | REGENERON PHARMACEUTICALS, INC. | Devices and methods for precision dose delivery |
Aug, 2040
(17 years from now) | |
USD961377 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Aug, 2040
(17 years from now) | |
US11472861 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(17 years from now) | |
US11459374 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) | |
US11459373 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) |
Ingredients: AFLIBERCEPT
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US11053280 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) | |
US11306135 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) | |
US11299532 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) | |
US11186625 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) | |
US11174283 | REGENERON PHARMACEUTICALS, INC. | Anti-VEGF protein compositions and methods for producing the same |
Aug, 2040
(17 years from now) | |
US11104715 | REGENERON PHARMACEUTICALS, INC. | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants |
Aug, 2040
(17 years from now) |
Ingredients: AFLIBERCEPT
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic